Evidence map›Paper›PMID 31641403›Full record

ArticleThe World Allergy Organization journal2019

Challenges and choices in the pharmacological treatment of non-severe pediatric asthma: A commentary for the practicing physician.

Omer Kalayci, Hanan Abdelateef, César Fireth Pozo Beltrán, Zeinab A El-Sayed, René Maximiliano Gómez, Elham Hossny, Mário Morais-Almeida, Antonio Nieto, Wanda Phipatanakul, Paulo Pitrez and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 9 countries.

Omer KalayciPediatric Allergy and Asthma, Hacettepe University, School of Medicine, Ankara, Turkey.
Hanan AbdelateefPediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.
César Fireth Pozo BeltránAlergia e Inmunología Clínica Pediátrica, Hospital Infantil de México Federico Gómez, Mexico.
Zeinab A El-SayedPediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.
René Maximiliano GómezSchool of Health Sciences, Catholic University of Salta, Argentina.
Elham HossnyPediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt.
Mário Morais-AlmeidaCentro de Alergia dos Hospitais CUF, Lisbon, Portugal.
Antonio NietoPediatric Pulmonology & Allergy Unit Children's Hospital la Fe, 46026, Valencia, Spain.
Wanda PhipatanakulPediatric Allergy and Immunology, Boston Children's Hospital, Boston, MA, USA.
Paulo PitrezSchool of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Gary Wk WongDepartment of Paediatrics, The Chinese University of Hong Kong, China.
Paraskevi XepapadakiAllergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
Nikolaos G PapadopoulosAllergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
Ain Shams University Hospital · EGBoston Children's Hospital · USChinese University of Hong Kong · CNHacettepe University · TRHospital Infantil de México Federico Gómez · MXNational and Kapodistrian University of Athens · GRPontifícia Universidade Católica do Rio Grande do Sul · BRUniversidad Católica de Salta · ARUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, asthma research has focused intensely on the severe part of the disease spectrum, leading to new treatments, mostly therapeutic monoclonal antibodies. However, severe asthma accounts for not more than 2% of asthma in the pediatric population. Therefore, non-severe asthma remains a major health problem in children, not only for patients and parents but also for healthcare professionals such as general practitioners, pediatricians and allergists who take care of these patients. It is thus essential to identify and put in context novel concepts, applicable to the treatment of these patients. Recent evidence suggests benefits from using anti-inflammatory treatment even for the mildest cases, for whom until now only symptomatic bronchodilation was recommended. Likewise, "reliever" medication may be better combined with an inhaled corticosteroid (ICS). Among "new" treatments (for children), ICS formulation in ultrafine particles has showed promise and tiotropium is gaining access to the pediatric population. Maintenance and reliever therapy (MART) is an option for moderate disease. Most importantly, personalized response to medications appears to be considerable, therefore, it may need to be taken into account. Overall, these new options provide opportunities for multiple new management strategies. The deployment of such strategies in different populations remains to be evaluated.

Indexed as

MARTMild asthmaModerate asthmaPharmacotherapyTreatment

Identifiers

PMID31641403
PMCPMC6796770
OpenAlexW2978238560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.